Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2005
10/06/2005WO2005092320A1 Cytoprotective composition
10/06/2005WO2005092314A1 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer
10/06/2005WO2005092310A2 Chemically stable compositions of 4-hydroxy tamoxifen
10/06/2005WO2005069894A3 Conformationally constrained smac mimetics and the uses thereof
10/06/2005WO2004037321A3 Immunotherapy of cancer through controlled cell lysis
10/06/2005US20050223430 Gntiii expression in plants
10/06/2005US20050222423 Carboxylic acid derivative
10/06/2005US20050222420 Chain oligolactic acid thioester
10/06/2005US20050222418 Novel tyloindicines and related processes, pharmaceutical compositions and methods
10/06/2005US20050222414 N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control
10/06/2005US20050222410 Inhibitors of histone deacetylase
10/06/2005US20050222392 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
10/06/2005US20050222387 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/06/2005US20050222253 Anti-cancer nitro- and thia-fatty acids
10/06/2005US20050222249 Softgel of NLKJ for treating prostate diseases
10/06/2005US20050222248 3'-hydroxy-dihydrodaidzein, 5-hydroxy-O-demethylangolesin; for treating hormone dependent conditions and other diseases and disorders; anticarcinogenic agents; menopausal syndrome; osteoporosis; rheumatic diseases; atherosclerosis; premenstrual syndrome; coronary artery spasm; vascular diseases
10/06/2005US20050222244 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
10/06/2005US20050222243 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
10/06/2005US20050222238 Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
10/06/2005US20050222237 Inhibitors of glycogen synthase kinase-3 (GSK-3), a serine/threonine protein kinase; for treatment and prevention of diabetes and Alzheimer's disease
10/06/2005US20050222230 3,4-diarylpyrazoles and their use in the therapy of cancer
10/06/2005US20050222224 p53 Inhibitors and therapeutic use of the same
10/06/2005US20050222199 Process for the preparation of a hydrate of an antranilic acid derivative
10/06/2005US20050222197 Novel pyrazolopyridine derivatives as pharmaceutical agents
10/06/2005US20050222194 3-[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-quinolin-2(1H)-ones or 5--[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-pyrrolo[3,2,1-IJ]quinolin-4(4H)-ones; type E antagonists; analgesics, antipyretics, antiinflammatory agents; side effect reduction
10/06/2005US20050222189 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors
10/06/2005US20050222183 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
10/06/2005US20050222174 N-{4-[1-(2,6-difluorobenzyl)-3-(4-fluorophenyl)-5-({methy[2-(2-oxo-1-piperidinyl)ethyl]amino}methyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-N'-ethylurea; antagonistic action for gonadotropin-releasing hormone
10/06/2005US20050222172 Active ingredient in treating neurodegenerative disease, Alzheimer's disease caused by abnormal enzyme activity
10/06/2005US20050222167 Amidation of 3-(acidinylamino)-5-methylolanilines with 5-[4-phenylpiperazin-1-yl(thio)carbonylamino]nicotinic acids and the product, which have antitumor activity and low toxicity.
10/06/2005US20050222160 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(1-oxypyridin-2-yl)thiazol-5-yl]methanone, used for inhibiting proliferation of lymphocytes in a host, and for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, arthritis, multiple sclerosis, diabetes
10/06/2005US20050222155 Inhibitors of akt activity
10/06/2005US20050222139 Non-peptide gnrh antagonists
10/06/2005US20050222133 Process for preparing pyrrolo[2, 1-c] [1,4] benzodiazepine hybrids
10/06/2005US20050222116 Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue
10/06/2005US20050222114 Use of new etonogestrel esters
10/06/2005US20050222100 Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
10/06/2005US20050222097 Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity
10/06/2005US20050222087 Hedgehog antagonists that inhibit the hedgehog pathway in a smoothened gain-of-function cell with an IC50 within a factor of 20, 10, or even a factor of 5, of the IC50 with which they inhibit the hedgehog pathway in a patched-null cell
10/06/2005US20050222084 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
10/06/2005US20050222065 Vascular therapeutics
10/06/2005US20050222041 oligopeptides capable of stimulating neural cell adhesion molecule (NCAM) signalling and/or interfering with cell adhesion, used for treatment of nervous system disorders
10/06/2005US20050222020 Apoptotically active peptides
10/06/2005US20050222017 Apoptosis promoter and inhibitor interacting with cgi-94, and method of screening the same
10/06/2005US20050221489 Recombinant negative strand virus rna expression systems and vaccines
10/06/2005US20050221440 Nucleic acid containing a reading frame with a first sequence encoding segments of the tumor associated antigen, PRAME (preferentially expressed antigen in melanoma); immunogenic; cluster sequences have affinity for a same Major Histocompatibility Complex receptor peptide binding cleft
10/06/2005US20050221435 Biological material for preparing pharmaceutical compositions intended for treating mammals
10/06/2005US20050221420 Nogo receptor homologues and their use
10/06/2005US20050221395 Methods and products based on oligomerization of stress proteins
10/06/2005US20050221391 Reagents and methods for identification of binding agents
10/06/2005US20050221368 Methods for identifying RNA binding compounds
10/06/2005US20050221346 May be used to detect the presence of a cancer or to evaluate the prognosis of a known disease
10/06/2005US20050221317 Use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
10/06/2005US20050221303 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
10/06/2005US20050221292 Vectors with modified protease-dependent tropism
10/06/2005US20050221284 Heteropolymer complexes and methods for their use
10/06/2005US20050220899 Use of cisplatin in combination with folic acid for increasing cisplatin efficacy
10/06/2005US20050220859 Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD)
10/06/2005US20050220856 Phospholipid derivative
10/06/2005US20050220844 Oral preventive/therapeutic agent for skin damage containing diacylglyceryl ether
10/06/2005US20050220819 Novel binding epitopes for helicobacter pylori and use thereof
10/06/2005US20050220810 Anti-aging preparation
10/06/2005US20050220807 Methods of delivery of exogenous proteins to the cytosol and uses thereof
10/06/2005US20050220804 Increasing an immune response in an animal, comprising administering a compound (such as a carbohydrate, an antibiotic, a sugar, a protein, or an antibody) that binds a C-type lectin (but not the DEC-205 receptor) on the surface of a dendritic cell
10/06/2005US20050220790 Amino-terminally truncated rantes as chemokine antagonists
10/06/2005US20050220786 Lyophilised preparation comprising antibodies against the efg receptor
10/06/2005US20050220757 Chemokine mutants acting as chemokine antagonists
10/06/2005CA2610628A1 Combination therapy
10/06/2005CA2561696A1 Novel modified galectin 9 proteins and use thereof
10/06/2005CA2561192A1 Cancerous disease modifying antibodies
10/06/2005CA2561117A1 Decoy nucleic acid to synoviolin gene promoter
10/06/2005CA2560919A1 Uses of anti-ctla-4 antibodies
10/06/2005CA2560905A1 Conjugated psychotropic drugs and uses thereof
10/06/2005CA2560864A1 Cytotoxicity mediation of cells evidencing surface expression of cd63
10/06/2005CA2560862A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp
10/06/2005CA2560859A1 Cytotoxicity mediation of cells evidencing surface expression of cd44
10/06/2005CA2560696A1 Mutations of the pik3ca gene in human cancers
10/06/2005CA2560584A1 Novel compounds for modulating cell proliferation
10/06/2005CA2559532A1 Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen
10/06/2005CA2559036A1 9-substituted 8-oxoadenine compound
10/06/2005CA2559029A1 Complex particles and coated complex particles
10/06/2005CA2534445A1 Agent for promoting hgf production comprising heparin-like oligosaccharides
10/05/2005EP1582586A1 Apoptosis-associated protein and use thereof
10/05/2005EP1582517A1 Blood-brain barrier disruption inhibitors
10/05/2005EP1582219A1 Connexin 26 inhibitors and cancer metastasis inhibitors
10/05/2005EP1582210A2 Compositions and methods for treating or preventing surgical adhesions
10/05/2005EP1582207A1 Inhibitor for liver cancer onset and progress
10/05/2005EP1581790A2 Peptides that home to tumor lymphatic vasculature and methods of using same
10/05/2005EP1581616A2 Novel proteins and nucleic acids encoding same
10/05/2005EP1581614A2 Nucleotide sequences for gene regulation and methods of use thereof
10/05/2005EP1581557A2 Metastin derivatives and their use
10/05/2005EP1581552A2 Human and non-human primate homologues of nkd protein, nucleic acid sequences encoding, and uses thereof
10/05/2005EP1581547A2 Compounds resistant to metabolic deactivation and methods of use
10/05/2005EP1581536A2 Epothilone derivatives
10/05/2005EP1581534A2 Tumour-inhibiting annellated azepinone derivatives
10/05/2005EP1581531A1 Pyridino[2,3-d]pyrimidine derivatives as selectiive kdr and fgfr inhibitors
10/05/2005EP1581528A1 Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors
10/05/2005EP1581520A1 Compounds, compositions and methods
10/05/2005EP1581519A1 Ondansetron forms and processes of making the same
10/05/2005EP1581512A2 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents
1 ... 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 ... 2211